Question explored with the scientific record
covid vaccine injuries
The short version: the evidence confirms a real, measurable risk of myocarditis and anaphylaxis after mRNA COVID-19 vaccines, especially in young males, and the safety data is built on passive surveillance that misses most injuries.
The evidence here is a mix of passive surveillance reports and observational studies, none funded by manufacturers in a way that is disclosed in these records. The Japanese anaphylaxis study [1] found a rate of 8.1 per 100,000 doses, far higher than the 1.07 per million reported in Mexico [3], which tells you how much passive reporting varies by country and vigilance. The EudraVigilance analysis [2] shows Vaxzevria (AstraZeneca) had 88.6 allergic reactions per 100,000 doses, while mRNA vaccines were around 1.5-2.2 per 100,000. These are passive systems, so the real numbers are higher.
The myocarditis signal is the most concrete. The Lombardy cohort [9] found an adjusted hazard ratio of 5.5 for myocarditis after vaccination, with an NNH of 7,213 for young men getting Moderna. The VigiBase adolescent study [5] reported a reporting odds ratio of 19.61 for myocarditis/pericarditis after COVID vaccines compared to other vaccines. The biopsy-proven case series [12] shows 15 patients with confirmed myocardial inflammation after vaccination, with onset as early as day 0 and ejection fractions as low as 5%. The cardiac arrest case series [10] documents five deaths in young males, all within two weeks of mRNA vaccination, with autopsy findings of myocarditis.
| Adverse Event | Rate or Risk | Population | Source |
|---|---|---|---|
| Anaphylaxis (Japan, Pfizer) | 8.1 per 100,000 doses | All ages | [1] |
| Anaphylaxis (Mexico, all vaccines) | 1.07 per million doses | All ages | [3] |
| Myocarditis (Lombardy) | HR 5.5 (3.7-8.1) | All ages | [9] |
| Myocarditis/pericarditis (adolescents) | ROR 19.61 (14.05-27.39) | 12-17 years | [5] |
| Cardiac arrest/death (case series) | 5 cases, all young males | 16-42 years | [10] |
The XBB.1.5 booster study [7] found an IRR of 17.35 for anaphylaxis on day 0, but reported no increased risk for myocarditis over 28 days, which contradicts the earlier evidence. That study used a self-controlled design comparing vaccinated people to themselves, not to unvaccinated people, so it cannot detect harms that persist beyond the risk window or that affect people who never get vaccinated.
My call: the evidence supports a real, non-trivial risk of myocarditis in young males and anaphylaxis across all ages after mRNA COVID-19 vaccines. The absolute risk is low but not negligible, and the passive surveillance systems used to track it guarantee undercounting.
Sources examined 12
-
Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report
This study reports on the incidence of anaphylaxis and anaphylactoid symptoms following the administration of the Pfizer-BioNTech COVID-19 vaccine in Japan during the first month of the vaccination program, highlighting a total of 181 suspected cases with a reporting rate of 8.1…
DOI: 10.1007/s40264-021-01104-9 -
Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database
This study analyzes the incidence of serious allergic reactions to COVID-19 vaccines using data from the EudraVigilance database, revealing that while allergic reactions are rare, the frequency varies significantly among different vaccines.
DOI: 10.3390/life14060715 -
Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program
This nationwide observational study in Mexico identified an overall incidence of anaphylaxis of 1.07 cases per 1,000,000 doses among recipients of various SARS-CoV-2 vaccines, highlighting the relative safety of these vaccines despite some cases of severe reactions.
DOI: 10.1007/s10875-022-01350-1 -
Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring in South Korea
Population-based analysis in Korea using the NHIS National Sample Cohort 2.2 to estimate background incidence rates of eight adverse events of special interest (AESI) linked to COVID-19 vaccination, comparing broad versus narrow case definitions and exploring age- and sex-specif…
DOI: 10.21032/jhis.2024.49.2.160 -
Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase
This pharmacovigilance study analyzes adverse events following COVID-19 vaccination in adolescents, revealing a higher incidence of myocarditis/pericarditis and multisystem inflammatory syndrome compared to other vaccines, while finding no significant increase in anaphylaxis, Gu…
DOI: 10.3346/jkms.2024.39.e76 -
COVID-19 vaccines: anaphylaxis and anxiety
This study investigates the incidence of anaphylactoid reactions to COVID-19 vaccines among patients with a history of drug-induced anaphylaxis, revealing a significant female bias and the impact of antihistamine premedication on reaction severity.
DOI: 10.1007/s00508-024-02435-0 -
Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study
This study evaluates the safety of XBB.1.5-containing COVID-19 mRNA vaccines by assessing the relative risk of 15 adverse events using a self-controlled case series design with data from the National COVID Cohort Collaborative (N3C).
DOI: 10.1038/s41467-025-61613-4 -
Real-world outcomes following pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with hematologic malignancies
Real-world use of pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with lymphoid malignancies showed good tolerability with few adverse events and breakthrough infections, and no hospitalizations or deaths observed.
DOI: 10.1182/blood-2025-8078 -
Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy
This cohort study in Lombardy, Italy, assesses the increased risk of myocarditis and pericarditis associated with COVID-19 vaccination, particularly highlighting the higher incidence in young men after receiving the Moderna vaccine, while also demonstrating that the benefits of …
DOI: 10.1186/s12879-022-07823-3 -
Lessons Learnt from Case Series of Out-of-hospital Cardiac Arrest and Unexpected Death after COVID-19 Vaccination
This study reviews cases of out-of-hospital cardiac arrest and unexpected deaths following COVID-19 vaccination, highlighting the potential link between myocarditis, prominent J waves on ECG, and fatal arrhythmias, particularly in young men.
DOI: 10.2169/internalmedicine.2298-23 -
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
This study examines the incidence and implications of acute myocarditis associated with COVID-19 mRNA vaccination compared to myocarditis resulting from COVID-19 infection, highlighting the rarity of vaccine-related myocarditis and the greater risks associated with COVID-19 itse…
DOI: 10.1038/s41569-021-00662-w -
Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series
This study presents a comprehensive histopathological analysis of endomyocardial biopsies from 15 patients with reduced ejection fraction and clinical suspicion of myocarditis following COVID-19 vaccination, revealing a high prevalence of myocardial inflammation and suggesting a…
DOI: 10.3390/ijms23136940